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To the Editor: Recently, we read with interest and pleasure
Coca et al.’s1 systematic review of the accuracy and reliability
of serum and urinary biomarkers for the diagnosis and risk
stratification of acute kidney injury (AKI). One of Coca
et al.’s findings is that serum cystatin C (CysC) performed
best for early as well as differential diagnosis of established
AKI.
Timing for the detection of early-stage renal impairment
is extremely important, especially in the therapeutic manage-
ment of complex illness. In an acute condition, the absence of
a reliable biomarker and the reliance on serum Cr (sCr)
markedly delays the diagnosis and, consequently, the
institution of therapy. Recently, research interest on the role
of serum CysC in an intensive care unit (ICU) population has
been stopped after the presumed association of CysC with
inflammatory biomarkers in non-critically ill patients.2
We retrospectively reviewed all laboratory data referral to
1000 patients (611 mean, mean age 64.3 years) admitted in
the ICU or the post-cardiac surgery intensive care unit
(PCSICU). PCSICU population was submitted to extra-
corporeal circulation during cardiac surgical intervention. A
total of 3993 samples tested contemporaneously for sCr,
CysC and C-reactive protein (CRP) were selected (Table 1).
Renal replacement therapy and known thyreopathy were
exclusion criteria. No correlations between CysC vs CRP and
sCr vs CRP were found either in ICU or in PCSICU.
Moreover, we observed a well-known correlation between sCr
and CysC in our entire population (r¼ 0.739, Po0.01). Our
results are encouraging for the resumption of the use of CysC
for monitoring renal function in critically ill patients. Large
multicenter studies in ICU populations are needed for
definitive approval or not of serum CysC in early AKI
diagnosis.
1. Coca SG, Yalavarthy R, Concato J et al. Biomarkers for the diagnosis and
risk stratification of acute kidney injury: a systematic review. Kidney Int
2008; 73: 1008–1016.
2. Knight EL, Verhave JC, Spiegelman D et al. Factors influencing serum
cystatin C levels other than renal function and the impact on renal
function measurement. Kidney Int 2004; 65: 1416–1421.
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We read with interest the letter in response to our
systematic review and the new data from Ferrannini
et al.,1 which demonstrates that serum cystatin C is not
correlated with C-reactive protein and is strongly corre-
lated with serum creatinine. We agree that more studies
investigating the utility of serum cystatin C in acute
kidney injury (AKI) for critically ill patients should be
conducted.
It is important, however, to not just correlate cystatin C
concentration with serum creatinine concentration, as was
presented in the study. The objective of the novel
biomarker studies should be to replace serum creatinine
or strengthen the current diagnostic and prognostic
assessment along with serum creatinine. Thus, it is
important to design studies and perform analyses, that
would delineate other attributes of the new diagnostic tool
rather than mimicking the diagnostic abilities of serum
creatinine. For example, a study by Herget-Rosenthal
et al.,2 demonstrated that the rise in serum cystatin C
preceded the rise in serum creatinine by 1.5±0.6 days.
This study also compared the performance of cystatin C
against clinically meaningful end points, including the
RIFLE definitions for AKI and dialysis-requiring AKI.
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Table 1 | Mean and standard deviation (s.d.) of age, sCr, CysC
and C-reactive protein (CRP) in our ICU population
Age
(years)
Cystatin C
(0.55–0.95 mg/l)
CRP (o5 mg/
100 ml)
Creatinine
(0.7–1.2 mg/100 ml)
Women
N 1662 1662 1662 1661
Mean 65.4 1.94 102.8 0.97
s.d. 16.1 1.14 95.5 0.75
Men
N 2331 2331 2331 2328
Mean 58.9 1.786 105.7 1.16
s.d. 18.1 1.08 97.7 1.10
Total
N 3993 3993 3993 3989
Mean 61.6 1.85 104.5 1.08
s.d. 17.6 1.10 96.8 0.97
CysC, cystatin C; ICU, intensive care unit; sCr, serum Cr.
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Thus, the three major goals of future biomarker studies,
as discussed in our review, should be the following: (1) to
differentiate types of AKI at the time of diagnosis (acute
tubular necrosis vs. prerenal vs. other); (2) to predict or
diagnose AKI earlier than the ‘delayed’ clinical diagnosis
via creatinine; (3) to predict hard outcomes (need for
dialysis, length of stay, death) at the time of injury.3
In the absence of associations between biomarkers and
these hard end points, the availability of another
biomarker that ‘mimics’ creatinine will not be beneficial
in advancing the field of AKI. We would encourage
Ferrannini et al. to perform the analyses we have
mentioned in order to determine how cystatin C performs
for predicting these types of end points.
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the targets
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To the Editor: The article by Davenport et al.1 suggests that
improved blood pressure control increases intradialytic
hypotension. It is unlikely that the reported higher incidence
of hypotension is caused by trying to achieve the Renal
Association targets alone.
In a study of 991 dialysis treatments in 111 patients over a
3-week period, we documented predialysis blood pressures of
136.9±23.4/67.8±14.0 mm Hg and postdialysis blood
pressures of 133.0±24.0/65.8±12.5 mm Hg. The Renal
Association targets were achieved by 56.8% of patients
predialysis, 44.1% postdialysis, and 37.8% achieved both
targets. Intradialytic hypotension occurred in 2.4% of all
treatments. No significant differences were demonstrated in
the blood pressure, interdialytic weight gains or prescribed
medication of those who experienced hypotension and those
who did not.
Two critical factors implemented in our unit may
contribute to these findings. We recognize that short dialysis
times make ultrafiltration more difficult to tolerate and
increase the potential for hypotension. Longer treatment
times are utilized whenever possible with the modal dialysis
time being 4.5 h. Our center utilizes postdilution hemodiafil-
tration as standard. There is increasing evidence that the use
of hemodiafiltration is associated with improvements in
blood pressure control, incidence of intradialytic hypotension
and a reduction in mortality.2–4
Predialysis hypertension does not obviate hypotension
episodes5 and not having targets for blood pressure control
will not necessarily reduce the frequency of hypotension
episodes. When improved control of blood pressure is
desired, modifications to the dialysis treatment itself should
be considered as part of the management strategy.
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High blood pressure is a major health issue in all regions of
the world,1 and myocardial infarction and stroke are the
commonest causes of death and disability worldwide.2
However, although there is a strong relationship between
blood pressure and the risk of cardio- and cerebrovascular
disease in the general population,1,2 this relationship is less
clear for hemodialysis patients, despite the increased
incidence of hypertension in this patient group. Assuming
a normal distribution, then the 95% confidence limits for
pre-dialysis blood pressure recordings were 183/95–91/
39 mm Hg, and 181/91–85/41 mm Hg post-dialysis record-
ings for the patients dialysing in Kilmarnock, and as such
only just over one-third of patients achieved the current
KDOQI blood pressure targets. Thus even in a single unit,
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